D. Boral Capital Webinar Series
Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Tuesday, September 30th
10:00 am – 11:00 am EST
Join Jason Kolbert, Managing Director of Healthcare Research at D. Boral Capital and Dr. Roger Pomerantz, M.D. & Vice Chairman of Enlivex Therapeutics for an exclusive virtual panel discussion featuring Professor Philip Conaghan MBBS, PhD, FRACP, FRCP, a leading clinician scientist working in the field of musculoskeletal medicine and Professor Ali Mobasheri BSc, ARCS, MSc, DPhil (Oxon), a leading scientist working in the area of musculoskeletal biology.
This webinar will explore recent breakthroughs in treatment approaches, with a focus on new clinical insights from Enlivex’s knee osteoarthritis program.
Our expert panel will provide key perspectives on the evolving therapeutic landscape for musculoskeletal conditions, discuss the role of Allocetra in treating knee pain, and dive into the significance of the latest data.
Don't miss this unique opportunity to hear directly from the experts shaping the future of inflammatory disease treatment and musculoskeletal conditions.
Disclaimers
Enlivex Therapeutics Ltd. (ENLV) is currently or has been considered to be a client of D. Boral Capital, or one of its affiliates, within the past 12 months.
D. Boral Capital or its affiliates provide Investment Banking Services to Enlivex Therapeutics Ltd. (ENLV).
D. Boral Capital, or its affiliates, have received compensation from Enlivex Therapeutics Ltd. (ENLV) for investment banking services within the past 12 months.
Moderator
Jason Kolbert
Managing Director of Healthcare Research,
D. Boral Capital
Panelists
Dr. Roger Pomerantz, M.D.
Vice Chairman,
Enlivex Therapeutics
Professor Philip Conaghan
Prof of Musculoskeletal Medicine, University of Leeds
& Director, NIHR Leeds Biomedical Research Centre











